BUZZ - Bank of America gives Diodes a "Buy" rating, driving its stock price up

On October 6, the shares of credit scoring giant Fair Isaac (FICO.N) fell 2.4% in after-hours trading, closing at $679.01. The company announced it would cut approximately 15% of its workforce to streamline management, simplify operations, and integrate AI-driven product development. Affected employees started receiving notifications during the week of October 5. The company expects the restructuring plan to be substantially complete by the third quarter of fiscal year 2027. Fair Isaac anticipates a pre-tax charge of around $27 million in the fourth quarter of fiscal year 2026, mainly related to severance packages and employee costs, with most of these expenses expected to result in future cash outflows. By the close of the previous trading day, Fair Isaac’s share price had declined by about 59% year to date. (For the convenience of non-English speakers, Reuters has automated the translation of its reports into several other languages. As automated translation may contain errors or lack necessary context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for readers’ convenience. Reuters is not liable for any damages or losses resulting from the use of the automated translation function.)

On October 6th, shares of biotech company Caribou Biosciences (CRBU.O) fell by 36.1% in after-hours trading to $0.73. The company announced it is exploring potential sale, merger, or other options to unlock shareholder value. Caribou plans to discontinue the development of its experimental cell therapy vispa-cel for a certain blood cancer, as well as CB-011 for treating the bone marrow cancer—multiple myeloma. The company stated that vispa-cel is ready for clinical trials, and it has reached an agreement with the FDA on the design for late-stage clinical trials. However, the difficult financing environment for allogeneic CAR-T therapies has made it challenging to raise the necessary funds to advance these projects. Caribou also intends to lay off employees and cut costs; according to its report, as of June 30, 2026, the company held $113.8 million in cash, cash equivalents, and marketable securities. As of the previous trading day’s close, the stock had fallen about 29% year-to-date. (For the convenience of non-English speakers, Reuters provides automated translation of its reports into several languages. As automated translations may contain errors or lack context, Reuters does not guarantee the accuracy of automated translation texts and provides them solely for reader convenience. Reuters assumes no liability for any harm or loss from use of the automated translation feature.)

This article was automatically generated using Dow Jones technology. Shares of Vanguard FTSE Emerging Markets ETF were flat at $60.62 Tuesday on what proved to be an overall favorable trading session for the U.S. stock market, with the S&P 500 Index rising 0.6% to 7,818.93. This was the fund's third consecutive day of gains. The ETF's shares closed 1.5% below the 52-week high of $61.53 seen on September 4, 2026. Trading volume was 4,661,177, compared to the 65-day average trading volume of 7,016,590. As of October 5, the fund's net asset value totaled $60.76 per share. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:37 ET (20:37 GMT)

This article was automatically generated by Dow Jones using technology from Automated Insights. Shares of Novavax Inc. shed 9.9% to $11.32 on what proved to be an all-around favorable trading session for the stock market, with the NASDAQ Composite Index rising 0.4% to 27,599.79 and the Dow Jones Industrial Average rising 0.5% to 51,521.28. Novavax Inc. closed 15.4% below its 52-week high of $13.39, which the company achieved on October 5th. The stock underperformed when compared to some of its peers, as Johnson & Johnson rose 0.7% to $254.78, Pfizer Inc. rose 0.3% to $27.50, and Merck & Co. Inc. rose 1.72% to $141.94. Trading volume totaled 19.3 million, compared to the 50-day average of 5.3 million. Data source: Dow Jones Market Data, FactSet (END) Dow Jones Newswires October 06, 2026 16:33 ET (20:33 GMT)